ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice

Atherosclerosis
Naoki TerasakaToshimori Inaba

Abstract

The objective of the present study was to determine whether a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, pactimibe sulfate (CS-505), could reduce atherosclerotic lesions beyond and independent of the reduction achieved by cholesterol lowering alone from two different types of lesions. (1) Early lesion model. Twelve-week-old apolipoprotein E (apoE)(-/-) mice were treated with 0.03 or 0.1% (w/w) CS-505, 0.1 or 0.3% avasimibe (CI-1011), or 3% cholestyramine for 12 weeks. Each treatment significantly reduced plasma cholesterol by a similar degree (43-48%). The antiatherosclerotic activity of 0.1% CS-505, however, was more efficacious than the effects of the other treatments (90% versus 40-50%). (2) Advanced lesion model. Twenty-four-week-old apoE(-/-) mice were treated with 0.03 or 0.1% CS-505 or 0.1% CI-1011 for 12 weeks. CS-505 at 0.1% revealed enhanced lesion reduction compared with 0.1% CI-1011 (77% versus 54%), whereas the plasma cholesterol-lowering effect of 0.1% CS-505 was almost the same as that of 0.1% CI-1011. Furthermore, immunohistochemical analysis demonstrated that CS-505 significantly reduced the number of macrophages and expression of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-13. These data...Continue Reading

References

Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·Z S GalisP Libby
Sep 23, 2000·Nature·A J Lusis
Feb 13, 2001·The Journal of Clinical Investigation·S FazioR V Farese
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emily L WillnerRobert V Farese
Oct 23, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Dwayne E DoveSergio Fazio
Nov 13, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Nancy LevinIra G Schulman
May 14, 2005·Current Opinion in Lipidology·Shinji Yokoyama
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos

❮ Previous
Next ❯

Citations

Sep 7, 2007·Accounts of Chemical Research·Hiroshi Tomoda, Takayuki Doi
Nov 10, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·James X RongEdward A Fisher
Nov 22, 2011·Future Medicinal Chemistry·Taichi Ohshiro, Hiroshi Tomoda
Jun 26, 2009·Expert Opinion on Therapeutic Patents·M T Chhabria, B M Mahajan
Jul 9, 2010·Biochemical and Biophysical Research Communications·Courtney Netherland, Douglas P Thewke
Mar 29, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Li HanJun-Rong Du
Dec 4, 2014·Expert Opinion on Therapeutic Patents·Taichi Ohshiro, Hiroshi Tomoda
Apr 23, 2015·The Journal of Antibiotics·Keisuke KobayashiHiroshi Tomoda
Dec 9, 2014·Frontiers in Physiology·Fabian LindenChristian A Gleissner
Sep 12, 2014·Journal of Lipid Research·Paul A Dawson, Saul J Karpen
Oct 5, 2018·Journal of Atherosclerosis and Thrombosis·Hisataka YamazakiShun Ishibashi
May 2, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Masakatsu KotsumaKenji Nishimura
Dec 7, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Masakatsu KotsumaHideo Saji
Sep 5, 2015·The Journal of Pharmacology and Experimental Therapeutics·Taichi OhshiroHiroshi Tomoda
Sep 27, 2019·Pharmacological Reviews·Dongdong WangAtanas G Atanasov
Mar 11, 2020·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Hanna RuhanenVesa M Olkkonen

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.